Ultragenyx is trading 6.18% lower at $15.60 in after-hours trading after its November 3 earnings release announced a roughly 20% workforce reduction and termination of its UX701 Wilson disease program. - Third-quarter revenue was $173 million, above the cited $155.6 million estimate; the company reaffirmed its 2027 profitability outlook. - Shares closed at $16.63 in the November 3 regular session. Trading volume or activity-level data was not provided.